In situ production and secretion of proteins endow therapeutic benefit against psoriasiform dermatitis and melanoma
Open Access
- 18 December 2023
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (52)
Abstract
Genetic medicines have the potential to treat various diseases; however, certain ailments including inflammatory diseases and cancer would benefit from control over extracellular localization of therapeutic proteins. A critical gap therefore remains the need to develop and incorporate methodologies that allow for posttranslational control over expression dynamics, localization, and stability of nucleic acid–generated protein therapeutics. To address this, we explored how the body’s endogenous machinery controls protein localization through signal peptides (SPs), including how these motifs could be incorporated modularly into therapeutics. SPs serve as a virtual zip code for mRNA transcripts that direct the cell where to send completed proteins within the cell and the body. Utilizing this signaling biology, we incorporated secretory SP sequences upstream of mRNA transcripts coding for reporter, natural, and therapeutic proteins to induce secretion of the proteins into systemic circulation. SP sequences generated secretion of various engineered proteins into the bloodstream following intravenous, intramuscular, and subcutaneous SP mRNA delivery by lipid, polymer, and ionizable phospholipid delivery carriers. SP-engineered etanercept/TNF-α inhibitor proteins demonstrated therapeutic efficacy in an imiquimod-induced psoriasis model by reducing hyperkeratosis and inflammation. An SP-engineered anti-PD-L1 construct mediated mRNA encoded proteins with longer serum half-lives that reduced tumor burden and extended survival in MC38 and B16F10 cancer models. The modular nature of SP platform should enable intracellular and extracellular localization control of various functional proteins for diverse therapeutic applications.Keywords
Funding Information
- HHS | NIH | National Institute of Biomedical Imaging and Bioengineering (R01 EB025192-01A1)
- HHS | NIH | National Cancer Institute (P30 CA142543)
This publication has 46 references indexed in Scilit:
- Acceptable changes in quality attributes of glycosylated biopharmaceuticalsNature Biotechnology, 2011
- Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 AxisThe Journal of Immunology, 2009
- Protein therapeutics: a summary and pharmacological classificationNature Reviews Drug Discovery, 2008
- The level of synthesis and secretion of Gaussia princeps luciferase in transfected CHO cells is heavily dependent on the choice of signal peptideJournal of Biotechnology, 2007
- Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNAImmunity, 2005
- A mammalian homolog of SEC61p and SECYp is associated with ribosomes and nascent polypeptides during translocationCell, 1992
- Transient involvement of signal recognition particle and its receptor in the microsomal membrane prior to protein translocationCell, 1983
- Translocation of proteins across the endoplasmic reticulum. I. Signal recognition protein (SRP) binds to in-vitro-assembled polysomes synthesizing secretory protein.Journal of Cell Biology, 1981
- Translocation of proteins across the endoplasmic reticulum III. Signal recognition protein (SRP) causes signal sequence-dependent and site-specific arrest of chain elongation that is released by microsomal membranes.Journal of Cell Biology, 1981
- Translocation of proteins across the endoplasmic reticulum. II. Signal recognition protein (SRP) mediates the selective binding to microsomal membranes of in-vitro-assembled polysomes synthesizing secretory protein.Journal of Cell Biology, 1981